Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study

por Kristensen, Lars Erik, Keiserman, Mauro, Papp, Kim, McCasland, Leslie, White, Douglas, Lu, Wenjing, Soliman, Ahmed M, Eldred, Ann, Barcomb, Lisa, Behrens, Frank
Publicado 2022

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

por Kristensen, Lars Erik, Keiserman, Mauro, Papp, Kim, McCasland, Leslie, White, Douglas, Lu, Wenjing, Wang, Zailong, Soliman, Ahmed M, Eldred, Ann, Barcomb, Lisa, Behrens, Frank
Publicado 2022